{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T02:05:52Z","timestamp":1771466752440,"version":"3.50.1"},"reference-count":67,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Hypertrophic cardiomyopathy (HCM) is a heterogeneous cardiac disease and one of its major challenges is the limited accuracy in stratifying the risk of sudden cardiac death (SCD). Positron emission tomography (PET), through the evaluation of myocardial blood flow (MBF) and metabolism using fluorodeoxyglucose (FDG) uptake, can reveal microvascular dysfunction, ischemia, and increased metabolic demands in the hypertrophied myocardium. These abnormalities are linked to several factors influencing disease progression, including arrhythmia development, ventricular dilation, and myocardial fibrosis. Fibroblast activation can also be evaluated using PET imaging, providing further insights into early-stage myocardial fibrosis. Conflicting findings underscore the need for further research into PET\u2019s role in risk stratification for HCM. If PET can establish a connection between parameters such as abnormal MBF or increased FDG uptake and SCD risk, it could enhance predictive accuracy. Additionally, PET holds significant potential for monitoring therapeutic outcomes. The aim of this review is to provide a comprehensive overview of the most significant data on disease progression, risk stratification, and prognosis in patients with HCM using cardiac PET-CT imaging.<\/jats:p>","DOI":"10.3390\/diagnostics15020133","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T07:40:13Z","timestamp":1736322013000},"page":"133","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["PET-CT Imaging in Hypertrophic Cardiomyopathy: A Narrative Review on Risk Stratification and Prognosis"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2639-4058","authenticated-orcid":false,"given":"Patr\u00edcia","family":"Marques-Alves","sequence":"first","affiliation":[{"name":"Cardiology Department, Coimbra Hospital and University Center, 3004-561 Coimbra, Portugal"},{"name":"Faculty of Medicine, University of Coimbra, 3004-548 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9255-3064","authenticated-orcid":false,"given":"Lino","family":"Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Cardiology Department, Coimbra Hospital and University Center, 3004-561 Coimbra, Portugal"},{"name":"Faculty of Medicine, University of Coimbra, 3004-548 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8952-8618","authenticated-orcid":false,"given":"Maria Jo\u00e3o","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Cardiology Department, Coimbra Hospital and University Center, 3004-561 Coimbra, Portugal"},{"name":"Faculty of Medicine, University of Coimbra, 3004-548 Coimbra, Portugal"},{"name":"Instituto Ci\u00eancias Nucleares Aplicadas \u00e0 Sa\u00fade (ICNAS), 3000-548 Coimbra, Portugal"},{"name":"Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT), 3000-548 Coimbra, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.hrthm.2015.12.048","article-title":"Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy","volume":"13","author":"Maron","year":"2016","journal-title":"Heart Rhythm."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Task Force Members, Elliott, P.M., Anastasakis, A., Borger, M.A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A.A., Lafont, A., and Limongelli, G. (2014). 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J., 35, 2733\u20132779.","DOI":"10.1093\/eurheartj\/ehu284"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","article-title":"2020 AHA\/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy","volume":"76","author":"Ommen","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0735-1097(99)00056-X","article-title":"Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy","volume":"33","author":"Elliott","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2015.02.061","article-title":"Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies","volume":"65","author":"Maron","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.amjcard.2019.07.023","article-title":"Prognostic Role of Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Low-to-Intermediate Sudden Cardiac Death Risk Score","volume":"124","author":"Todiere","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1161\/01.CIR.102.8.858","article-title":"Epidemiology of Hypertrophic Cardiomyopathy\u2013Related Death","volume":"102","author":"Maron","year":"2000","journal-title":"Circulation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jacc.2018.05.060","article-title":"Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function","volume":"72","author":"Mentias","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC)","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2014.05.003","article-title":"Hypertrophic Cardiomyopathy: Present and Future, With Translation Into Contemporary Cardiovascular Medicine","volume":"64","author":"Maron","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","first-page":"313","article-title":"Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: Systematic review of clinical risk markers","volume":"12","author":"Christiaans","year":"2010","journal-title":"EP Eur."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0735-1097(03)00941-0","article-title":"American College of Cardiology\/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European S","volume":"42","author":"Maron","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(12)60397-3","article-title":"Hypertrophic cardiomyopathy","volume":"381","author":"Maron","year":"2013","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.112.136085","article-title":"Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age","volume":"127","author":"Maron","year":"2013","journal-title":"Circulation."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jacc.2005.04.043","article-title":"Gender-Related Differences in the Clinical Presentation and Outcome of Hypertrophic Cardiomyopathy","volume":"46","author":"Olivotto","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00059-018-4700-8","article-title":"Risk stratification in hypertrophic cardiomyopathy","volume":"45","author":"Marrakchi","year":"2020","journal-title":"Herz."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e005820","DOI":"10.1161\/CIRCEP.117.005820","article-title":"Clinical Course and Quality of Life in High-Risk Patients with Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators","volume":"11","author":"Maron","year":"2018","journal-title":"Circ. Arrhythmia Electrophysiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1253\/circj.CJ-14-0203","article-title":"Late gadolinium enhancement and prognosis of hypertrophic cardiomyopathy","volume":"78","author":"Sakuma","year":"2014","journal-title":"Circ. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/CRD.0000000000000002","article-title":"The prognostic impact of myocardial late gadolinium enhancement","volume":"22","author":"Panovsky","year":"2014","journal-title":"Cardiol. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s12350-018-1299-3","article-title":"Can positron emission tomography help stratify the risk of sudden cardiac death in patients with hypertrophic cardiomyopathy?","volume":"26","author":"Kay","year":"2019","journal-title":"J. Nucl. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jacc.2011.05.018","article-title":"Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations","volume":"58","author":"Olivotto","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1007\/s00259-016-3465-7","article-title":"Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: A 2016 reappraisal","volume":"43","author":"Castagnoli","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2967\/jnumed.111.096156","article-title":"PET\/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy","volume":"53","author":"Bravo","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100452","DOI":"10.1016\/j.ijcha.2019.100452","article-title":"Positron emission tomography (15O-water, 11C-acetate, 11C-HED) risk markers and nonsustained ventricular tachycardia in hypertrophic cardiomyopathy","volume":"26","author":"Magnusson","year":"2020","journal-title":"IJC Heart Vasc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s12350-018-1298-4","article-title":"Is there a role for cardiac positron emission tomography in hypertrophic cardiomyopathy?","volume":"26","author":"Bravo","year":"2019","journal-title":"J. Nucl. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s12350-019-01595-1","article-title":"82Rb myocardial perfusion PET\/CT after anterior\/antero-septal wall myectomy","volume":"26","author":"Caobelli","year":"2019","journal-title":"J. Nucl. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s13139-013-0201-0","article-title":"Myocardial Fibrosis in Hypertrophic Cardiomyopathy Demonstrated by Integrated Cardiac F-18 FDG PET\/MR","volume":"47","author":"Kong","year":"2013","journal-title":"Nucl. Med. Mol. Imaging."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF03164836","article-title":"Myocardial glucose metabolism in patients with hypertrophic cardiomyopathy: Assessment by F-18-FDG PET study","volume":"12","author":"Uehara","year":"1998","journal-title":"Ann. Nucl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s12350-016-0686-x","article-title":"Cardiac imaging with 18F-fluorodeoxyglucose PET\/MRI in hypertrophic cardiomyopathy","volume":"24","author":"Takeishi","year":"2017","journal-title":"J. Nucl. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e221052","DOI":"10.1148\/radiol.221052","article-title":"Myocardial Activity at 18F-FAPI PET\/CT and Risk for Sudden Cardiac Death in Hypertrophic Cardiomyopathy","volume":"306","author":"Wang","year":"2023","journal-title":"Radiology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1053\/j.semnuclmed.2020.02.016","article-title":"PET and SPECT Tracers for Myocardial Perfusion Imaging","volume":"50","author":"Klein","year":"2020","journal-title":"Semin. Nucl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/j.semnuclmed.2020.02.011","article-title":"15O-Water PET MPI: Current Status and Future Perspectives","volume":"50","author":"Maaniitty","year":"2020","journal-title":"Semin. Nucl. Med."},{"key":"ref_33","first-page":"264","article-title":"Potential of [11C]acetate for measuring myocardial blood flow: Studies in normal subjects and patients with hypertrophic cardiomyopathy","volume":"17","author":"Timmer","year":"2010","journal-title":"J Nucl Cardiol Off. Publ. Am. Soc. Nucl. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1161\/CIRCULATIONAHA.106.657023","article-title":"Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: New insights from multiparametric magnetic resonance imaging","volume":"115","author":"Petersen","year":"2007","journal-title":"Circulation"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2967\/jnumed.107.050138","article-title":"Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy","volume":"49","author":"Sotgia","year":"2008","journal-title":"J. Nucl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"H986","DOI":"10.1152\/ajpheart.00233.2007","article-title":"Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy","volume":"294","author":"Knaapen","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.97.3.230","article-title":"Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation","volume":"97","author":"Krams","year":"1998","journal-title":"Circulation"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1161\/01.CIR.75.6.1130","article-title":"Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy","volume":"75","author":"Tanaka","year":"1987","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1007\/s12350-020-02344-5","article-title":"PET myocardial perfusion imaging in the diagnosis of apical hypertrophic cardiomyopathy","volume":"29","author":"Sanghani","year":"2022","journal-title":"J. Nucl. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/hrt.2006.110460","article-title":"Assessment of intravascular and extravascular mechanisms of myocardial perfusion abnormalities in obstructive hypertrophic cardiomyopathy by myocardial contrast echocardiography","volume":"93","author":"Knaapen","year":"2007","journal-title":"Heart"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s12350-015-0158-8","article-title":"Apparent left ventricular cavity dilatation during PET\/CT in hypertrophic cardiomyopathy: Clinical predictors and potential mechanisms","volume":"23","author":"Bravo","year":"2016","journal-title":"J. Nucl. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1161\/CIRCIMAGING.112.000110","article-title":"The Relationship of Delayed Enhancement by Magnetic Resonance to Myocardial Perfusion by Positron Emission Tomography in Hypertrophic Cardiomyopathy Paco","volume":"6","author":"Bravo","year":"2013","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jacc.2009.04.026","article-title":"Cardiac Magnetic Resonance Detection of Myocardial Scarring in Hypertrophic Cardiomyopathy: Correlation With Histopathology and Prevalence of Ventricular Tachycardia","volume":"54","author":"Kwon","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/CIRCULATIONAHA.104.494476","article-title":"Molecular basis of arrhythmias","volume":"112","author":"Shah","year":"2005","journal-title":"Circulation"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1161\/CIRCEP.113.000600","article-title":"Effects of regional mitochondrial depolarization on electrical propagation: Implications for arrhythmogenesis","volume":"7","author":"Zhou","year":"2014","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1093\/oxfordjournals.eurheartj.a015204","article-title":"Syncope and ventricular arrhythmias in hypertrophic cardiomyopathy are not related to the derangement of coronary microvascular function","volume":"18","author":"Lorenzoni","year":"1997","journal-title":"Eur. Heart J."},{"key":"ref_47","first-page":"139","article-title":"Stress Myocardial Blood Flow Heterogeneity is a Positron Emission Tomography Biomarker of Ventricular Arrhythmias in Patients with Hypertrophic Cardiomyopathy","volume":"176","author":"Lu","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s12350-018-01521-x","article-title":"Higher incidence of vasodilator-induced left ventricular cavity dilation by PET when compared to treadmill exercise-ECHO in hypertrophic cardiomyopathy","volume":"27","author":"Lu","year":"2020","journal-title":"J. Nucl. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa025050","article-title":"Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy","volume":"349","author":"Cecchi","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s12350-020-02346-3","article-title":"The next step in improving (semi-)quantitative MPI PET","volume":"29","author":"Koenders","year":"2022","journal-title":"J. Nucl. Cardiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s12350-020-02266-2","article-title":"Activity regimes for 82Rb cardiac PET: Effects on absolute MBF and MPI","volume":"29","author":"Hoff","year":"2022","journal-title":"J. Nucl. Cardiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s12149-017-1167-2","article-title":"Incidental spade-shaped FDG uptake in the left ventricular apex suggests apical hypertrophic cardiomyopathy","volume":"31","author":"Katagiri","year":"2017","journal-title":"Ann. Nucl. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2967\/jnumed.111.090662","article-title":"The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: A systematic review and metaanalysis including the Ontario experience","volume":"53","author":"Youssef","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1536\/ihj.20-552","article-title":"Hypertrophic Cardiomyopathy Complicated by Cardiac Sarcoidosis Diagnosed by Both the Morphological Abnormalities and the Time Course of the Disease","volume":"62","author":"Miki","year":"2021","journal-title":"Int. Heart J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s12350-019-01623-0","article-title":"Occasionally increased 18F-FDG uptake in apical hypertrophic cardiomyopathy on serial follow-up PET\/CT","volume":"26","author":"Norikane","year":"2019","journal-title":"J. Nucl. Cardiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/0002-9149(92)91313-S","article-title":"Differences in myocardial fluoro-18 2-deoxyglucose uptake in young versus older patients with hypertrophic cardiomyopathy","volume":"69","author":"Kagaya","year":"1992","journal-title":"Am. J. Cardiol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Aoyama, R., Takano, H., Kobayashi, Y., Kitamura, M., Asai, K., Amano, Y., Kumita, S.-I., and Shimizu, W. (2017). Evaluation of myocardial glucose metabolism in hypertrophic cardiomyopathy using 18F-fluorodeoxyglucose positron emission tomography. PLoS ONE., 12.","DOI":"10.1371\/journal.pone.0188479"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jccase.2017.04.004","article-title":"Occasionally increased 18F-fluorodeoxyglucose uptake in apical hypertrophic cardiomyopathy in mid-ventricular obstruction","volume":"16","author":"Yamamoto","year":"2017","journal-title":"J. Cardiol. Cases"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s12350-022-02931-8","article-title":"What is this image? 2022 image 5 result: Apical ring uptake on 18F-FDG PET\/CT indicating apical hypertrophic cardiomyopathy with apical aneurysm","volume":"29","author":"Miyamoto","year":"2022","journal-title":"J. Nucl. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ijcard.2005.01.069","article-title":"Partial myocardial fibrosis in hypertrophic cardiomyopathy demonstrated by 18F-fluoro-deoxyglucose positron emission tomography and multislice computed tomography [5]","volume":"107","author":"Funabashi","year":"2006","journal-title":"Int. J. Cardiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.yjmcc.2015.10.005","article-title":"Has the search for a marker of activated fibroblasts finally come to an end?","volume":"88","year":"2015","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"(68)Ga-FAPI PET\/CT: Tracer Uptake in 28 Different Kinds of Cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1007\/s00259-021-05674-9","article-title":"Fibroblast activation protein imaging in reperfused ST-elevation myocardial infarction: Comparison with cardiac magnetic resonance imaging","volume":"49","author":"Xie","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_64","first-page":"881","article-title":"Cardiac fibroblast activation in dilated cardiomyopathy detected by positron emission tomography","volume":"29","author":"Shi","year":"2022","journal-title":"J. Nucl. Cardiol. Off. Publ. Am. Soc. Nucl. Cardiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/RLU.0000000000005530","article-title":"Heterogeneous Uptake of Al18F-NOTA-FAPI and 18F-FDG in Apical Aneurysm in Apical Hypertrophic Cardiomyopathy","volume":"49","author":"Xu","year":"2024","journal-title":"Clin. Nucl. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00259-023-06411-0","article-title":"Functional significance of myocardial activity at (18)F-FAPI PET\/CT in hypertrophic cardiomyopathy identified by cardiac magnetic resonance feature-tracking strain analysis","volume":"51","author":"Zhang","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"375","DOI":"10.31083\/j.rcm2510375","article-title":"A Systematic Review and Meta-analysis of Efficacy and Safety of Mavacamten for the Treatment of Hypertrophic Cardiomyopathy","volume":"25","author":"Zheng","year":"2024","journal-title":"Rev. Cardiovasc. Med."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/2\/133\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:24:55Z","timestamp":1759919095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/2\/133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":67,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["diagnostics15020133"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15020133","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]}}}